Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Document › Details

Kiadis Pharma N.V.. (3/13/18). "Press Release: Kiadis Pharma Raises €23.4 Million in a Private Placement of 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam.

	Organisation	Kiadis Pharma N.V. (Euronext: KDS)
	Group	Kiadis (Group)
	Organisation 2	Jefferies International Ltd.
	Group	Leucadia (Group)
	Product	ATIR101™ (Kiadis)
	Product 2	investment banking
	Index term	Kiadis–SEVERAL: investment, 201803 private placement €23.4m w 2.6m new shares €9/share to institutional investors
	Person	Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)
	Person 2	Hård, Karl (Kiadis 201709–201812 Head IR + Communications LEFT 1/19 before Redx Pharma + AstraZeneca)

Original document
accessed by [iito] on 2018-03-28

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Kiadis (Group)

[1] SynOx Therapeutics Ltd.. (7/27/21). "Press Release: SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer". Dublin....
[2] Kiadis Pharma N.V.. (11/2/20). "Press Release: Sanofi Offers to Acquire Kiadis for €308 Million". Paris & Amsterdam....
[3] Byondis B.V.. (8/19/20). "Press Release: Byondis Announces Appointment of Chief Financial Officer". Nijmegen....
[4] Kiadis Pharma N.V.. (7/13/20). "Press Release: Kiadis Appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team". Amsterdam....
[5] Kiadis Pharma N.V.. (7/8/20). "Press Release: Kiadis Licenses Previously Undisclosed Pre-clinical K-NK-cell Programs to Sanofi, with Total Potential Deal Value of €875 Million, plus Royalties". Amsterdam....
[6] Kiadis Pharma N.V.. (11/12/19). "Press Release: Kiadis Pharma Changes Strategy to Focus Solely on Development of Natural Killer (NK) Cell Therapeutics and Terminates Development of ATIR101". Amsterdam....
[7] Kiadis Pharma N.V.. (10/22/19). "Press Release: Kiadis Pharma Announces Formation of Renowned Scientific Advisory Board". Amsterdam....
[8] Kiadis Pharma N.V.. (10/17/19). "Press Release: Kiadis Pharma Provides Regulatory Update on ATIR101". Amsterdam....
[9] Kiadis Pharma N.V.. (9/10/19). "Press Release: Kiadis Pharma Announces Results for the Six Months Ended June 30, 2019". Amsterdam....
[10] Kiadis Pharma N.V.. (8/19/19). "Press Release: Kiadis Pharma Announces Investor Events for September 2019". Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]